PMEF
AGIO icon

Point72 Middle East FZE’s Agios Pharmaceuticals AGIO Stock Holding History

Point72 Middle East FZE’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-27,754
Closed -$618K – 48
2023
Q4 		$618K Buy
+27,754
New +$622K 0.02% 755

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Middle East FZE's AGIO Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Agios Pharmaceuticals (AGIO) in Q1 2024, closing a stake of 27,754 shares — an estimated $618K sold.

Point72 Middle East FZE first reported a position in AGIO in Q4 2023 and held it in 1 quarter. The position peaked at $618K in Q4 2023. 186 funds tracked by Wall St. Rank hold AGIO as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Agios Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 27,754 Agios Pharmaceuticals shares in Q1 2024, an estimated $618K.
  • Point72 Middle East FZE first reported a position in Agios Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Agios Pharmaceuticals position peaked at $618K in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.